Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Addition of Myeloablative Doses of Total Marrow Irradiation (TMI) to Myeloablative Fludarabine/Busulfan Conditioning for Allogeneic HSCT in Patients with High-Risk AML, CML, or Myelodysplastic Syndrome: A Phase II Clinical Trial

Lucas Maahs, Matthew Koshy, Karen Sweiss, Kang-hyun Ahn, Zhengjia Chen, Chukwuemeka Uzoka, Carlos Galvez, Paul Rubinstein, John Quigley, Santosh L. Saraf, Ana Maria Avila Rodriguez, Bulent Aydogan, Nadim Mahmud, Damiano Rondelli

Blood (2023) 142 (Supplement 1): 4897.

https://doi.org/10.1182/blood-2023-179270

Published: 2023

Journal Articles

Long-Term Adverse Events of Total Marrow Irradiation (TMI)-Based Conditioning Chemotherapy in Hematopoietic Stem Cell Transplant Recipients Treated on a Phase I/II Trial

Lucas Maahs, Pritesh Patel, Karen Sweiss, Chukwuemeka Uzoka, Nadim Mahmud, Ana Maria Avila, Matthew Koshy, Damiano Rondelli

Blood (2022) 140 (Supplement 1): 12913–12914.

https://doi.org/10.1182/blood-2022-163424

Published: 2022

Journal Articles

Stable Engraftment with Haploidentical Peripheral Blood Stem Cell Transplantation in Adult Patients with Sickle Cell Disease

Santosh L. Saraf, MD, Pritesh Patel, MB, CHB, Karen Sweiss, PharmD, Oh Annie, MD, Matthew Koshy, MD, Sally Campbell-lee, MD, Michel Gowhari, DO, Shivi Jain, MD, David Peace, MD, John G. Quigley, MD, Irum Khan, MBBS, Robert E. Molokie, MD, Nadim Mahmud, MBBS, PhD, Victor R. Gordeuk, MD, Damiano Rondelli, MD

Blood (2017) 130 (Supplement 1): 4591.

https://doi.org/10.1182/blood.V130.Suppl_1.4591.4591

Published: 2017

Journal Articles

A Phase 1 Study of Total Marrow Irradiation Combined with High-Dose Melphalan for Patients with Relapsed/ Refractory Multiple Myeloma

Pritesh R. Patel, MB, ChB, Annie L. Oh, MD, Matthew Koshy, MD, Bulent Aydogan, PhD, Karen Sweiss, PharmD, John G. Quigley, MD, Santosh L. Saraf, MD, Irum Khan, MD, Eileen D. Hacker, PhD APN, AOCN, Nadim Mahmud, MD PhD, David J. Peace, MD, Howard Ozer, MD PhD, Jennifer Windhorst, APN, Ralph R Weichselbaum, MD, Damiano Rondelli, MD

Blood (2016) 128 (22): 4646.

https://doi.org/10.1182/blood.V128.22.4646.4646

Published: 2016

Journal Articles

Alemtuzumab/Low Dose Radiation Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients with Sickle Cell Disease (SCD)

Santosh L. Saraf, MD, Annie L. Oh, MD, Dolores Mahmud, PhD, Pritesh R. Patel, MB, ChB, Karen Sweiss, PharmD, Matthew Koshy, MD, Sally Campbell-Lee, MD, Michel Gowhari, DO, Johara Hassan, MD, David Peace, MD, John G. Quigley, MD, Irum Khan, MBBS, Robert E. Molokie, MD, Lewis L. Hsu, MD PhD, Nadim Mahmud, MD PhD, Dennis J Levinson, MD, Victor R. Gordeuk, MD, Damiano Rondelli, MD

Blood (2014) 124 (21): 2703.

https://doi.org/10.1182/blood.V124.21.2703.2703

Published: 2014

Journal Articles

Myeloablative Fludarabine/ IV Busulfan Combined With Linac Based Intentsity Modulated Total Marrow Irradiation (IM-TMI) In Allogeneic Stem Cell Transplant For High Risk Hematologic Malignancies: A Phase I Study

Pritesh R. Patel, MB, ChB, Annie L. Oh, MD, Matthew Koshy, MD, Bulent Aydogan, PhD, Nadim Mahmud, MD, PhD, David Peace, MD, John G. Quigley, MD, Santosh L. Saraf, MD, Enzo DeMasi, MD, Ralph R Weichselbaum, MD, Damiano Rondelli, MD

Blood (2013) 122 (21): 3285.

https://doi.org/10.1182/blood.V122.21.3285.3285

Published: 2013

NARROW

Addition of Myeloablative Doses of Total Marrow Irradiation (TMI) to Myeloablative Fludarabine/Busulfan Conditioning for Allogeneic HSCT in Patients with High-Risk AML, CML, or Myelodysplastic Syndrome: A Phase II Clinical Trial

Long-Term Adverse Events of Total Marrow Irradiation (TMI)-Based Conditioning Chemotherapy in Hematopoietic Stem Cell Transplant Recipients Treated on a Phase I/II Trial

Stable Engraftment with Haploidentical Peripheral Blood Stem Cell Transplantation in Adult Patients with Sickle Cell Disease

A Phase 1 Study of Total Marrow Irradiation Combined with High-Dose Melphalan for Patients with Relapsed/ Refractory Multiple Myeloma

Alemtuzumab/Low Dose Radiation Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients with Sickle Cell Disease (SCD)

Myeloablative Fludarabine/ IV Busulfan Combined With Linac Based Intentsity Modulated Total Marrow Irradiation (IM-TMI) In Allogeneic Stem Cell Transplant For High Risk Hematologic Malignancies: A Phase I Study

Email alerts

ASH Publications

American Society of Hematology

Addition of Myeloablative Doses of Total Marrow Irradiation (TMI) to Myeloablative Fludarabine/Busulfan Conditioning for Allogeneic HSCT in Patients with High-Risk AML, CML, or Myelodysplastic Syndrome: A Phase II Clinical Trial

Long-Term Adverse Events of Total Marrow Irradiation (TMI)-Based Conditioning Chemotherapy in Hematopoietic Stem Cell Transplant Recipients Treated on a Phase I/II Trial

Stable Engraftment with Haploidentical Peripheral Blood Stem Cell Transplantation in Adult Patients with Sickle Cell Disease

A Phase 1 Study of Total Marrow Irradiation Combined with High-Dose Melphalan for Patients with Relapsed/ Refractory Multiple Myeloma

Alemtuzumab/Low Dose Radiation Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients with Sickle Cell Disease (SCD)

Myeloablative Fludarabine/ IV Busulfan Combined With Linac Based Intentsity Modulated Total Marrow Irradiation (IM-TMI) In Allogeneic Stem Cell Transplant For High Risk Hematologic Malignancies: A Phase I Study

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only